Latest News

New York, NY – Anavex Life Sciences was hit with a stock selloff on Tuesday after it posted topline results from a Phase II/III study for its candidate ANAVEX2-73 in pediatric patients with Rett syndrome. The study’s co-primary endpoint of the Clinical Global Impression-Improvement scale (CGI-I) was not reached, according...
COLUMBUS, Ohio — Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced that it has been selected by Ultragenyx to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company’s UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS...
GUILDFORD, SURREY – ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression...
Its emerging rare disease unit is driving sales growth for ANI Pharmaceuticals Inc. Looking ahead the company wants to build and expand rare disease drug sales. “The first imperative is scaling up our rare disease business,” said Nikhil Lalwani, chief executive of ANI, in a morning earnings conference call with...
SAN JOSE, Calif. — Anixa Biosciences, Inc., a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.” Anixa Chairman and CEO Dr....
SAN JOSE, Calif. — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin,...
BRISBANE, Calif. — Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today outlined its strategic priorities for 2024 with late-stage clinical milestones, including ANX005 for Guillain-Barré syndrome (GBS), ANX007 for geographic atrophy (GA) and its first-in-kind oral small...
ATLANTA —  Purple Pansies, a pancreatic cancer nonprofit organization, recently held its 12th annual Pillars of Hope Gala, presented by Kroger, raising more than $1 million in one evening to help fund pancreatic cancer research at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. The gala...